PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAdalimumab
Humira, Trudexa(adalimumab)
Abrilada, Amgevita, Amjevita, Amsparity, Cyltezo, Hadlima, Hefiya, Hukyndra, Hulio, Humira, Hyrimoz, Idacio, Imraldi, Libmyris, Simlandi, Yuflyma, Yusimry (adalimumab) is an antibody pharmaceutical. Adalimumab was first approved as Humira on 2002-12-31. It is used to treat ankylosing spondylitis, crohn disease, hidradenitis suppurativa, juvenile arthritis, and psoriatic arthritis amongst others in the USA. It has been approved in Europe to treat ankylosing spondylitis, arthritis, crohn disease, hidradenitis suppurativa, and papulosquamous skin diseases amongst others. The pharmaceutical is active against tumor necrosis factor.
Download report
Favorite
COVID-19
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
digestive system diseasesD004066
eye diseasesD005128
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry (discontinued: Abrilada, Humira, Hyrimoz)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Adalimumab
Tradename
Proper name
Company
Number
Date
Products
HumiraadalimumabAbbVieN-125057 RX2002-12-31
9 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
abriladaBiologic Licensing Application2025-01-15
adalimumabBiologic Licensing Application2024-12-26
adalimumab-aacfBiologic Licensing Application2024-08-01
adalimumab-adbmBiologic Licensing Application2024-05-02
adalimumab-ryvkBiologic Licensing Application2024-07-12
amjevitaBiologic Licensing Application2024-08-29
cyltezoBiologic Licensing Application2024-05-02
hadlimaBiologic Licensing Application2024-06-28
hulioBiologic Licensing Application2024-05-28
humiraBiologic Licensing Application2024-05-16
Show 6 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
juvenile arthritisEFO_1002007D001171M08
psoriatic arthritisEFO_0003778D015535L40.5
hidradenitis suppurativa—D017497L73.2
ulcerative colitisEFO_0000729D003093K51
ankylosing spondylitisEFO_0003898D013167M45
rheumatoid arthritisEFO_0000685D001172M06.9
uveitisHP_0000554D014605H20.9
crohn diseaseEFO_0000384D003424K50
Agency Specific
FDA
EMA
Expiration
Code
adalimumab, Cyltezo, Boehringer Ingelheim Pharmaceuticals, Inc.
Date TBDInterchangeable excl.
adalimumab, Humira, AbbVie Inc.
2028-02-24Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AB: Tumor necrosis factor alpha (tnf-alpha) inhibitors
— L04AB04: Adalimumab
HCPCS
Code
Description
J0135
Injection, adalimumab, 20 mg
Clinical
Clinical Trials
766 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAdalimumab
INNadalimumab
Description
Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Use is generally only recommended in people who have not responded to other treatments. It is used by injection under the skin.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>6CR1:H|Heavy chain of adalimumab EFab (VH-IgE CH2) EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLY LQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPTVKILQSICDGGGHFPPTIQLLCLVSGYTPGTI QITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCAHHHHHH >6CR1:L|Light chain of adalimumab EFab (VL-IgE CH2) DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQP EDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTIQITWLEDGQVMDVD LSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSGKKCA
Identifiers
PDB3WD5, 4NYL, 6CR1
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201580
ChEBI ID—
PubChem CID—
DrugBankDB00051
UNII IDFYS6T7F842 (ChemIDplus, GSRS)
Target
Agency Approved
TNF
TNF
Organism
Homo sapiens
Gene name
TNF
Gene synonyms
TNFA, TNFSF2
NCBI Gene ID
7124
Protein name
tumor necrosis factor
Protein synonyms
APC1 protein, Cachectin, TNF, macrophage-derived, TNF, monocyte-derived, TNF-a, TNF-alpha, tumor necrosis factor ligand 1F, Tumor necrosis factor ligand superfamily member 2, tumor necrosis factor-alpha, tumor necrotic factor alpha
Uniprot ID
Q9UIV3
Mouse ortholog
Tnf (21926)
tumor necrosis factor (P06804)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Hadlima – Organon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Imraldi – Biogen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Yusimry – Coherus BioSciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Humira – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Humira – Alvotech
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Adalimumab
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 32,459 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abrilada, Adalimumab, Adalimumab-aacf, Adalimumab-adbm, Adalimumab-ryvk, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
709,883 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use